Αποτελέσματα Αναζήτησης
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
27 Ιαν 2021 · CABENUVA, a 2-drug co-packaged product of cabotegravir, a human immunodeficiency virus type-1 (HIV-1) integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse...
Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77...
21 Ιαν 2021 · The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type...
23 Δεκ 2021 · A long-awaited development to help stop the spread of HIV and AIDS was approved by the U.S. Food and Drug Administration this week, and scientists are calling it a game-changer.
ViiV Healthcare’s Cabenuva – copackaged cabotegravir and rilpivirine extended-release injectable suspensions – was approved by the U.S. Food and Drug Administration on January 21, 2021. Cabenuva is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are ...
22 Ιαν 2021 · [Yesterday] the U.S. Food and Drug Administration approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral ...
